Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0131 | 1 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0071 | 0.4142 | 1 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0131 | 1 | 1 |
Toxoplasma gondii | aldehyde dehydrogenase | 0.0131 | 1 | 1 |
Loa Loa (eye worm) | TAR-binding protein | 0.0071 | 0.4142 | 1 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0028 | 0 | 0.5 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0028 | 0 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0028 | 0 | 0.5 |
Brugia malayi | RNA binding protein | 0.0071 | 0.4142 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0071 | 0.4142 | 1 |
Echinococcus multilocularis | aldehyde dehydrogenase, mitochondrial | 0.0131 | 1 | 1 |
Mycobacterium tuberculosis | Probable aldehyde dehydrogenase | 0.0131 | 1 | 0.5 |
Leishmania major | aldehyde dehydrogenase, mitochondrial precursor | 0.0131 | 1 | 1 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0131 | 1 | 0.5 |
Mycobacterium ulcerans | aldehyde dehydrogenase | 0.0131 | 1 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0028 | 0 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0028 | 0 | 0.5 |
Schistosoma mansoni | aldehyde dehydrogenase | 0.0131 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0028 | 0 | 0.5 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0071 | 0.4142 | 1 |
Brugia malayi | TAR-binding protein | 0.0071 | 0.4142 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.